About Us
Our mission is to intercept cancer at the earliest stages when patients are most treatable.
Addressing the gaps with first generation MRD tests
SAGA has developed a next-generation MRD platform specifically designed to overcome the key limitations of earlier methods, enabling earlier detection and more reliable long-term monitoring.
Our headquarters and CLIA-certified laboratory is located in the heart of the life science ecosystem in Research Triangle Park, North Carolina, and additional facilities in Lund, Sweden. SAGA also partners with pharmaceutical and biotechnology companies, as well as commercial entities to support early through late-stage cancer development programs across a range of cancer types.
Cultural Pillars
Care
for our people
Support, growth, and well-being at our core
Compassion
for our patients
Patient-centered precision oncology
Deliver
on our promise
Accurate data on time, every time
“By tracking structural variants — stable, unique, and tumor-defining fingerprints of each patient’s cancer — Pathlight enables interception of recurrence at its most treatable and potentially curable stage,” commented Roopom Banerjee, Executive Chairman of SAGA Diagnostics. “Our goal is to deliver the most accurate, trusted results that provide assurance and support confident, informed treatment decisions. Our published, peer reviewed data demonstrates the clinical validity of Pathlight in breast cancer and its potential power across all solid tumors and heme malignancies. SAGA has further partnered with leading clinicians, institutions, and biopharma to bring Pathlight to market and best serve patients.”
Join #TeamSAGA
Join our accomplished team. SAGA combines world-class genomic expertise with a leadership team deeply experienced in molecular residual disease (MRD), all aligned around a compelling vision of intercepting cancer at the earliest stages when it’s most treatable.
